Diabetes Mellitus is a disorder of altered glucose and lipid metabolism having hyperglycemia as characteristic feature. Long term uncontrolled Diabetes Mellitus primarily leads to rise in microvascular and macrovascular events involving many organ systems. Strict glycemic control remains the key to avoid such complications. The management of Diabetes and its co-morbid conditions affect patients not only economically but also psychologically. Currently about nine different varieties of medications are being employed in treatment of Diabetes Mellitus. Even after having many varieties of drugs available co-morbid conditions associated with Diabetes Mellitus are on rise as the global burden of disease is also increasing. In last decade drugs against some new targets in management of Diabetes are approved Glucagon like Peptide-1 (GLP-1) agonist, Dipeptidyl Peptidase-IV (DPP-IV) inhibitors and Sodium-Glucose linked Transporter-2 (SGLT-2) inhibitors and Peroxisome Proliferator-activated receptor alpha and gamma agonist. Although numerous drugs are available roughly one third patients achieve desired glycemic control thats why newer drugs acting on novel targets are required. The objective of review is to throw light on newer drug targets which are in various stages of development to have latest drugs against Diabetes.
Key words: AMPK, GPR119, Glucokinase activator
|
